Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Randomised, Double Blind, Placebo Controlled, Parallel Group Study to Investigate the Safety, Effect on Cognition and Pharmacokinetic Profile of PYM50028 in Subjects With Mild Dementia of the Alzheimer's Type

NCT00130429 is registered in ClinicalTrials.gov with Phytopharm as lead sponsor.

NCT NCT00130429
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00130429 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Randomised, Double Blind, Placebo Controlled, Parallel Group Study to Investigate the Safety, Effect on Cognition and Pharmacokinetic Profile of PYM50028 in Subjects With Mild Dementia of the Alzheimer's Type
Lead sponsor
Phytopharm
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2004
Completion date
September 30, 2005
Enrollment
250
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease